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TGF-b proteins are main regulators of blood
vessel development and maintenance. Here,
we report an unprecedented link between
TGF-b signaling and arterial hypertension based
on the analysis of mice mutant for Emilin1, a cys-
teine-rich secreted glycoprotein expressed in
the vascular tree. Emilin1 knockout animals
display increased blood pressure, increased pe-
ripheral vascular resistance, and reduced vessel
size. Mechanistically, we found that Emilin1 in-
hibits TGF-b signaling by binding specifically to
the proTGF-b precursor and preventing its matu-
ration by furin convertases in the extracellular
space. In support of these findings, genetic inac-
tivation of Emilin1 causes increased TGF-b
signaling in the vascular wall. Strikingly, high
blood pressure observed in Emilin1 mutants is
rescued to normal levels upon inactivation of
a single TGF-b1 allele. This study highlights the
importance of modulation of TGF-b availability
in the pathogenesis of hypertension.
INTRODUCTION
Arterial hypertension is a major medical problem world-
wide, being a risk factor for kidney, cerebral, and coronary
heart diseases and affecting about one third of the adult
population (Staessen et al., 2003). Hypertension is a com-
plex trait with both genetic and environmental determi-
nants. Although it has been estimated that approximately
30%–50% of blood pressure variance is due to inherited
genes, the molecular basis of this disease remains largely
to be defined.Increase in arterial blood pressure levels is commonly
attained by an enhanced cardiac pumping and/or an in-
creased vascular resistance to blood flow. So far, studies
on the pathogenesis of hypertension have placed major
emphasis on smooth muscle and endothelial cells. In con-
trast, elastic extracellular matrix (ECM), another major
component of blood vessels, has been considered for
a long time to play only a passive role in the dynamic vas-
cular changes typical of hypertension. However, the use of
transgenic animals has recently changed this view, sug-
gesting a causative link between defects in elastic fiber
components and the pathogenesis of hypertension (Faury
et al., 2003).
A growth factor of key importance in both development
and pathophysiology of blood vessels is transforming
growth factor-b (TGF-b) (Agrotis et al., 2005). TGF-bs are
synthesized as large precursors (proTGF-b) that are
cleaved by proprotein convertases (Beck et al., 2002;
Annes et al., 2003). This processing step generates a latent
TGF-b complex from which the mature ligand must be fur-
ther released in order to interact with its receptor. Less es-
tablished is whether proTGF-b is cleaved intracellularly or
extracellularly: While earlier reports suggested an intracel-
lular cleavage, recent genetic evidence showed that the
TGF-b convertases are required extracellularly (Beck
et al., 2002). Of note, only a minor fraction of the total
TGF-b produced by the cells is made available for signal-
ing (Annes et al., 2003), suggesting that the balancing be-
tween maturation, sequestration, and presentation of
TGF-b represents a major regulatory step to set strength
and precise localization of TGF-b activity within tissues.
Yet surprisingly little is known on the molecules modulat-
ing such TGF-b regulatory events in vivo.
Here we provide a novel link between vascular hyper-
tension and dysregulated TGF-b signaling. Our entry point
into this field has been the analysis of Emilin1 knockout
mice. Emilin1 is a secreted glycoprotein associated withCell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 929
the extracellular matrix of blood vessels (Bressan et al.,
1993). Emilin1 deficiency causes systemic arterial hyper-
tension. Remarkably, Emilin1 binds only immature
proTGF-b and prevents its maturation by protein conver-
tases, thus unveiling a new tier of regulation essential for
TGF-b extracellular availability.
This study highlights the importance of ECM com-
ponents of the vascular system in the pathogenesis of
hypertension through the modulation of local TGF-b
availability.
RESULTS
Characterization of the Vascular System
of Emilin1 Mutant Mice
Emilin1 is the founding member of the EDEN gene super-
family, coding for secreted proteins whose hallmark is the
presence of a cysteine-rich motif defined as EMI domain
(Braghetta et al., 2004). Emilin1/ mice develop normally
and are morphologically indistinguishable from wild-type
littermates (Zanetti et al., 2004). This finding suggests ei-
ther compensatory effects from other Emilin-related pro-
teins or the presence of more subtle phenotypes in Emilin1
knockout mice.
Emilin1 is strongly expressed in the mouse cardiovascu-
lar system during development (Braghetta et al., 2004) and
in the adult (Figure 1A). This observation prompted us to
thoroughly investigate cardiovascular structure and
function of Emilin1/ animals. Strikingly, systemic blood
pressure was significantly increased in Emilin1 null mice
compared to wild-type littermates, as measured both non-
invasively (systolic blood pressure [SBP]: 120 ± 2 versus
101 ± 1, n = 46 per group, p < 0.01) and invasively by radio-
telemetry, which allows the characterization also of dia-
stolic blood pressure levels (Figure 1B). Remarkably,
even blood pressure of heterozygous animals was partially
increased (SBP: 112 ± 2, n = 13, p < 0.01), indicating hap-
loinsufficiency of Emilin1 gene for this phenotype. The high
blood pressure of mutant animals was observed at all ages
examined (from 2 to 12 months) with high penetrance
(100% of animals evaluated). However, the increase of ar-
terial pressure in mutant animals with C57BL/6 and CD1
genetic background was higher than that observed in
a mixed 129C57BL/6 background (mean blood pressure
[MBP] increase: 19.3% ± 3.2% versus 12.6% ± 5.3%).
To test whether the increase of blood pressure was de-
pendent on an enhanced cardiac function, we measured
cardiac output in anesthetized Emilin1 mutant mice and
their wild-type littermates by a pressure/volume tetrapolar
catheter. As shown in Figure 1C, cardiac output was sim-
ilar in both mouse strains. This latter finding was further
substantiated by measurement of a series of echocardio-
graphic and hemodynamic parameters of cardiac struc-
ture and function, which did not display any significant dif-
ference between Emilin1/ and their wild-type littermates
in young animals (Table S1). Therefore, cardiac function
did not account for the high blood pressure levels ob-930 Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc.served in mutant mice. In contrast, vascular resistance
was significantly augmented in Emilin1/ animals
(Figure 1C), thus suggesting that the hypertensive pheno-
type could be ascribed to vascular abnormalities.
To test whether the increased vascular resistance was
due to abnormal vascular contractility or relaxation, sec-
ond branch mesenteric arteries were explanted, mounted
in a myograph, and stimulated with vasoactive drugs. We
found no significant difference in the responses of mutant
and control arteries (Figures S1A and S1B), suggesting
that the increase of peripheral resistance observed in
Emilin1/ mice is unlikely due to an abnormal vascular
reactivity.
Stiffening of conductance arteries can be a further
cause of hypertension (Izzo and Shykoff, 2001). Conse-
quently, the mechanical properties of large arteries were
characterized in Emilin1 null mice to look for any significant
vascular abnormality. The deformation to increasing ap-
plied pressures was recorded on two different kinds of ar-
tery, such as aorta and carotid, mounted on a myograph.
The diameter versus pressure plots recorded for common
carotid artery and ascending aorta gave extensibility
values similar in Emilin1-deficient and control mice (Fig-
ures 1D and S1C; data not shown). However, this analysis
revealed an important difference between the two mouse
strains: the significant reduction of diameter of blood ves-
sels excised from Emilin1/ compared to wild-type ani-
mals at any applied pressure (Figure 1D). Furthermore,
this was confirmed by in vivo analysis of ascending aorta
by echocardiography (Figures 1E and S1D), by angiogra-
phy (Figure S1E), and by histological assessment of the
vasculature (Figures S1F and S1G). The imaging analysis
further clarified that the branches of the vascular tree
were not affected by the lack of Emilin1.
Since small blood vessels are the main determinants of
peripheral resistance and blood pressure homeostasis,
the analysis of the vessel size was extended to resistance
vessels. Strikingly, the diameter of isolated second-
branch mesenteric arteries under a defined pressure
was clearly reduced in Emilin1 null mice (Figure 1F;
429 ± 21 mm versus 351 ± 23 mm, n = 5 per group, p <
0.05), suggesting that the decrease in vessel diameter
was a generalized trait of Emilin1 null mice. Noteworthy,
the reduction in vessel diameter could be estimated in
the order of 20% in both C57BL/6 and CD1 background
but was less pronounced and more variable in mice with
a mixed 129  C57BL/6 genetic background (data not
shown), suggesting that this vascular trait could be under
the influence of modifier genes. Moreover, we found that
the lack of Emilin1 realizes a distinctive architecture of re-
sistance vessels with a global reduction of their dimen-
sions both in lumen and media thickness (Figure 1G).
Taken together, our data indicate that Emilin1 deficiency
does not affect wiring of the vascular system, cardiac per-
formance, and arterial extensibility. In contrast, lack of
Emilin1 leads to generalized reduction of blood vessel
diameter, increased peripheral resistance, and systemic
arterial hypertension.
Emilin1 Inhibits TGF-b Signaling through
the EMI Domain
To gain insights into the mechanisms by which Emilin1
controls vascular cell behavior, we focused on the primary
structure of the protein. Emilin1 is a multidomain protein:
An N-terminal cysteine-rich EMI domain is followed by
a coiled-coil, a short collagenous domain, and a C1q-like
repeat at the C terminus (Figure 2A). While it has been
shown that the C-terminal domain is involved in the oligo-
merization of Emilin1 and cell adhesion (Mongiat et al.,
2000), surprisingly little is known on the function of the
EMI domain.
Growth factors’ signaling is regulated by secreted mol-
ecules containing cysteine-rich repeats, typically also
found in various extracellular matrix components (Piccolo
et al., 1999). This notion prompted us to explore the possi-
bility that Emilin1 could also modulate growth factors’
activity through its EMI domain. To this end, we took ad-
vantage of the Xenopus embryo as a model system to
study signaling pathways in vivo and as a functional
read-out for the biological activity of Emilin1 versus endog-
enous or ectopic TGF-b ligands. Embryos were injected at
the two-cell stage with 2 ng of syntheticEmilin1mRNA into
the marginal zone and then permitted to develop in order
to monitor for the appearance of morphological abnormal-
ities. Despite cleaving normally, gastrulation was delayed
in Emilin1-expressing embryos, displaying trunk reduction
at the tadpole stage (Figure S2B and data not shown). Mo-
lecularly, injected embryos showed downregulation of
MyoD expression (a marker of paraxial mesoderm), as re-
vealed by in situ hybridization carried out at the neurula
stage (Figures 2B–2E). Importantly, this biological effect
was contributed by the EMI domain and was recapitulated
by the injection of mRNA coding for the sole EMI domain
(400 pg; Figure 2D), but not of mRNA coding for an Emilin1
molecule deleted of its EMI domain (2 ng, Emilin1DEMI;
Figure 2E). Overexpression of EMI domain at higher doses
(> 1 ng) caused the inhibition of mesoderm development
(Figure S2H) and led either to gastrulation failure or to de-
velopment of embryos with a severely reduced head and
trunk (n = 333, 65%; data not shown). Of note, these ef-
fects were similar to those of embryos injected with
mRNA coding for antagonists of Nodal, a TGF-b family
member, such as Cerberus Short (Piccolo et al., 1999) or
for cleavage mutant/dominant negative TGF-b ligands
(Eimon and Harland, 2002).
These observations raised the possibility that Emilin1
acts through its EMI domain as an inhibitor of TGF-b activ-
ity. To test this hypothesis, we first assayed the effects of
expressing Emilin1, Emilin1DEMI, and EMI domain on the
gene responses triggered by Nodal (Xnr-1) in explanted
animal cap cells. As shown in Figures 2F and 2G, the in-
duction of the mesoderm markers Xbra, Eomes, andMixer
triggered by Xnr-1 mRNA was antagonized by coinjection
of Emilin1 or EMI domain mRNA but not by coinjection of
Emilin1DEMI mRNA. Interestingly, Emilin1 was unable to
counteract the gene response induced by the lowest bio-
logically active dose of a constitutive-active form of theTGF-b receptor (Figure 2H), suggesting that Emilin1 oper-
ates upstream of the interaction of the ligand with its re-
ceptor. To assess the effect of Emilin1 on TGF-b ligands
other than Nodal, we carried out microinjection experi-
ments withEmilin1 and TGF-b3mRNAs. As detailed in Fig-
ures S2N–S2Q, Emilin1 was effective in antagonizing the
early and long-term phenotypic effects triggered by
TGF-b3 in Xenopus embryos.
In principle, the phenotypes induced by EMI-domain/
Emilin1 overexpression might be compatible with addi-
tional effects on other signaling pathways regulating me-
soderm development, such as those activated by BMP,
FGF, and Wnt growth factors. To address this specificity
issue, we compared by RT-PCR the gene responses
caused by injection of BMP2, eFGF, or Wnt8 mRNAs in
the absence or presence of coinjected EMI-domain
mRNA. As shown in Figures 2I–2K, EMI-domain was un-
able to counteract the inducing effects of these cytokines.
We conclude from these experiments that Emilin1 is a new
specific antagonist of TGF-b ligands.
Emilin1 Inhibits proTGF-b Processing
by Furin Convertases
Emilin1 may inhibit TGF-b by any of several mechanisms.
First, it might interfere with TGF-b secretion or maturation;
second, it could prevent the presentation or the interac-
tion of TGF-b ligands with cognate receptors; third, it
could act by sequestering either the immature or mature
ligand. To test whether the EMI-domain antagonized
TGF-b signaling upstream of TGF-b receptor binding,
we carried out radio-receptor binding assays using mono-
layers of HEK293T cells transfected with HA-tagged type II
TGF-b Receptor expression plasmid in the presence or
absence of a plasmid coding for a GPI-anchored version
of the EMI-domain. 125I-labeled TGF-b1 (20 pM) was
added to transfected cells and washed; the bound ligand
was crosslinked with DSS and then immunoprecipitated
with anti-HA antibody. As shown in Figure 3A, binding of
125I-TGF-b1 was competed by cold TGF-b1, though not
by EMI-domain.
To further test whether the EMI-domain could antago-
nize the activity of mature TGF-b irrespectively of compet-
ing with the TGF-b Receptor, we concentrated soluble
EMI-domain protein from the supernatant of transfected
HEK293T cells and tested it for its ability to inhibit the
activation of the PAI-1-luciferase (lux) reporter by TGF-b1
in Mv1Lu mink lung cells. Surprisingly, we found that PAI-
1-lux induction by recombinant/fully processed TGF-b1
protein was unaffected even by a 50-fold molar excess of
EMI-domain protein (data not shown). Similar results were
observed upon overexpression of full-length Emilin1 from
a transfected plasmid: As shown in Figure 3B, the induction
of the Smad reporter CAGA12-luciferase (CAGA12-lux) by
recombinant mature TGF-b1 protein was similar in cells ex-
pressing Emilin1 or a control cDNA (Figure 3B, lanes 1 and
2); in stark contrast, however, Emilin1 was very effective in
inhibiting induction of CAGA12-lux triggered by a cotrans-
fected TGF-b1 expression plasmid (i.e., encoding forCell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 931
Figure 1. Characterization of the Vascular Phenotype of Emilin1-Deficient Mice
(A) Detection of Emilin1 (green staining) in aorta from adult mouse by immunofluorescence. Nuclei (red) were labeled with propidium iodide solution.
Note the preferential location of the protein at the periphery of elastic lamellae. Bar = 25 mm.932 Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc.
biologically active proTGF-b1 C223S/C225S) (Figure 3B,
compare lanes 3 and 4). This effect was specific and relied
on the EMI-domain, as Emilin1DEMI had no effect and
transfection of the sole EMI-domain had similar, albeit
weaker, activity to that of full-length Emilin1 (Figure 3B,
lanes 5 and 6).
To validate these conclusions in more physiological
conditions, we compared the response of a natural
TGF-b target in normal and Emilin1 mutant primary mouse
embryonic fibroblasts (MEFs). For this purpose, we used
the promoter of the CDK-inhibitor p15Ink4b (p15-lux). As
shown in Figure 3C, the transcription from p15-lux is
higher in Emilin1 knockout cells when compared to wild-
type cells (lanes 1 and 2); remarkably, blockade of TGF-b
receptor activity in mutant cells with the drug SB431542
(Inman et al., 2002) reversed this effect (lane 3), indicating
that endogenous Emilin1 is required to restrain TGF-b ac-
tivity in MEFs. If Emilin1 limits endogenous TGF-b signal-
ing, Emilin1 deficiency should parallel with an enhanced
responsiveness to autocrine TGF-b synthesis. To test
this hypothesis, we treated wild-type and Emilin1 mutant
MEFs with a chemical inhibitor of JNK1/2 (SP600125); in-
deed, it has been recently shown that loss of JNK turns on
the transcription from the endogenous TGF-b1 promoter,
setting up a sustained production of autocrine TGF-b1 in
MEFs (Ventura et al., 2004). As shown in Figure 3D, using
p15-lux assays we found that Emilin1 mutant MEFs
display a greater sensitivity than wild-type MEFs to JNK
blockade, supporting the notion that lack of Emilin1
causes aberrant TGF-b signaling.
Next, we asked whether the biochemical target of
Emilin1 is proTGF-b1, namely, the immature and inactive
precursor of TGF-b1. HEK293T cells were transfected
with a proTGF-b1 expression construct alone or in combi-
nation with a plasmid directing the expression of EMI-
domain on the cell surface (Flag- and GPI-tagged)
(Figure 3E). Cell lysates were subjected to immunoprecip-
itation with anti-Flag antibody, and proteins copurifying
with the EMI-domain were analyzed by Western blot using
an anti-LAP antibody. As shown in Figure 3E, the EMI-
domain interacted with proTGF-b1.We then wished to verify that the EMI-domain interacted
specifically with pro-TGF-b1 rather than with the pro-
cessed small-latent complex (LAP bound to processed
TGF-b) or free LAP. To this end, we repeated the pull-
down experiments using EMI-domain with extracts con-
taining proTGF-b, LAP protein alone, or a precomplexed
LAP/TGF-b1. As shown in Figure 3F, the EMI-domain
bound efficiently only to proTGF-b1. This interaction also
occurred at physiological levels of Emilin1, as demon-
strated by the copurification of endogenous Emilin1 with
proTGFb1 (Figure 3G).
The proteolytic processing of the proTGF-b precursor is
an essential step in the formation of the biologically active
TGF-b ligand. Since Emilin1 can interact with proTGF-b1,
we tested whether its inhibitory activity on TGF-b signaling
relied on inhibition of the proteolytic clipping of proTGF-b.
HEK293T cells were transfected with plasmids expressing
proTGF-b1 alone or in combination with Emilin1 or EMI-do-
main. As shown in Figure 3H, immunoblot analysis of the
cell lysates and conditioned medium from these cultures
revealed that both Emilin1 and EMI-domain potently in-
hibited the cleavage of proTGF-b1 into LAP (46 kDa
band) and TGF-b1 ligand (12 kDa band), while having no ef-
fect on total proTGF-b1 synthesis (50 kDa band). This
conclusion was supported by the inhibition of Smad2
phosphorylation in HepG2 cells treated with the condi-
tioned media collected from cells expressing proTGF-b1
in the absence or presence of Emilin1 (Figure S3A).
The effect of Emilin1 is similar to that produced by treat-
ment of cells with RVKR-CMK, a drug blocking the activity
of endogenous furins (Figure 3I). Moreover, ectopic ex-
pression of the proprotein convertase SPC1 led to the ap-
pearance of a smaller 43 kDa band, whose formation was
also inhibited by transfected EMI-domain (Figure 3J). To
test the relevance of Emilin1 in limiting TGF-b1 processing
in vivo, we compared the steady state levels of transfected
proTGF-b1 in wild-type and Emilin1 knockout MEFs. As
shown in Figure 3K, lack of Emilin1 caused the disappear-
ance of the 50 kDa proTGF-b1 band (compare lanes 1 and
2); crucially, blockade of furin activity rescued the level of
proTGF-b1 in Emilin1/ MEFs (lane 3). Taken together,(B) Systolic and diastolic blood pressure evaluated in Emilin1+/+ and Emilin1/mice invasively by radiotelemetry in conscious mice (n = 3 per group).
*p < 0.05 versus wild-type mice. Data are mean ±SEM. Blood pressure continued to be higher in Emilin1/mice also during anesthesia (MBP: 116± 3
versus 101 ± 2 mmHg, p < 0.01).
(C) Cardiac output and total peripheral resistance (TPR) evaluated in wild-type and Emilin1 knockout mice by Millar catheter placed in the left ventricle
(n = 7 per group). *p < 0.05 versus wild-type mice. Data are mean ± SEM.
(D) Pressure-internal diameter (ID) relationship for common carotid arteries from Emilin1+/+ (empty diamonds) and Emilin1-deficient (filled squares)
mice. The arteries were placed on a Mulvany pressure system and subjected to increasing intraluminal pressure (n = 6 per group). Data are mean ±
SEM. Note that mutant vessels, although displaying a smaller diameter compared to wild-type at any applied pressure, do respond normally (similar
slope) to pressure increments. Values from mutants were significantly different from wild-type at any pressure (p < 0.05). These data were used to
calculate extensibility values as shown in Figure S1C.
(E) Detection of reduced diameter of ascending aorta in Emilin1 deficient mice. Left panels: B-mode (bidimensional mode) echocardiography images
to allow the appreciation of landmarks. Right panels: M-mode (mono-dimensional mode) imaging of the section selected as shown in the B-mode
image.
(F) Images of mesenteric arteries from control and Emilin1-deficient mice mounted in a Mulvany myograph showing reduction of vessel diameter.
(Bar = 50 mm).
(G) Evaluation of media cross-sectional area (MCSA) and media/lumen ratio (M/L) in mesenteric arteries from wild-type and Emilin1 mutant mice (n = 5
for each group). *p < 0.05 versus wild-type mice. Data are mean ± SEM.Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 933
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these findings suggest that Emilin1 (or the isolated EMI-
domain) protects proTGF-b from proteolytic activation.
Next, we wished to know whether the inhibition of TGF-
b1 by Emilin1 occurs in the intracellular or extracellular
space. To address this question, we prepared two popu-
lations of HEK293T cells—responding and stimulator
cells—and carried out cell-mixing experiments. The re-
sponding cells (indicated as R in Figure 3L) contained
the TGF-b reporter CAGA12-lux; the stimulator cells (indi-
cated as S in Figure 3L) were the source of TGF-b1. As ex-
pected, when stimulator cells were mixed with responding
cells, CAGA12-lux was induced (Figure 3L, lanes 1 and 3).
To establish where Emilin blocked proTGF-b1, full-length
Emilin1 expression plasmid (indicated as +E in Figure 3L)
was cotransfected in stimulator or responding cells. Re-
markably, the presence of Emilin1 either in the stimulator
or responding cells equally inhibited the TGF-b response
(Figure 3L, lanes 4 and 5), indicating that Emilin1 can oper-
ate non-cell-autonomously in antagonizing proTGF-b sig-
naling. To validate this conclusion at the endogenous
level, we carried out cell-mixing experiments using wild-
type and Emilin1 null MEFs (Figure 3M). In this setup, re-
sponding cells were transfected with the natural TGF-b re-
porter p15-lux, and the stimulator cells were induced to
increase the endogenous production of TGF-b1 by treat-
ment with JNK inhibitors (Ventura et al., 2004). Combina-
tions of wild-type responding with untreated wild-type or
Emilin1 knockout cells led to comparable basal levels of
transcription (Figure 3M, lanes 1 and 2), with higher levels
in the combination mutant responding/untreated mutant
cells (lane 3), in line with the enhanced TGF-b signaling
of mutant cells. As expected, upon induction of endoge-
nous TGF-b synthesis with the JNK inhibitor SP600125,
the combination knockout-responding/knockout-stimula-
tor gave stronger activation of p15-lux promoter than the
combination wild-type responding/wild-type stimulator
(lanes 4 and 5). Intriguingly, when the induced knockout-
stimulator cells were mixed with wild-type-responding
cells, the level of TGF-b signaling was similar to the full
wild-type combination (compare lanes 5 and 6); this sug-
gests that endogenous Emilin1 in the responding cells an-
tagonized proTGF-b extracellularly. This conclusion was
finally validated by using a nonsecretable KDEL-taggedEmilin1, a signal that has been shown to cause retention
of a secreted protein within the secretory vescicles up to
Trans-Golgi space. As shown in Figure 3N, cells trans-
fected with KDEL-Emilin1 actually displayed an enhanced,
rather than an inhibited, TGF-b1 responsiveness. Taken
together, these gain- and loss-of-function experiments in-
dicate that Emilin1 is relevant to prevent TGF-bprocessing
outside of the cell.
Reversal of the Emilin1 Null Hypertensive Phenotype
by Reduction of TGF-b Gene Dosage
Since TGF-b ligands and Emilin1 are coexpressed in vas-
cular smooth muscle cells of the aortic wall, the data pre-
sented above suggest that Emilin1 plays a role in restrain-
ing TGF-b effects within the vascular tissue. To test the
requirement of Emilin1 in the control of TGF-b signaling
in vivo, we searched for proof of increased TGF-b signaling
in the vascular system of Emilin1/ mice.
As a first indicator of TGF-b signaling, the relative abun-
dance of nuclei staining with antibodies to phospho-Smad2
(P-Smad2) was measured. The number of P-Smad2 pos-
itive nuclei were significantly increased in mutant aorta
(Figures 4A–4C). The construct CAGA12-GFP, in which
the GFP reporter gene is under the control of multimerized
TGF-b responsive elements, was used as a second, inde-
pendent read-out of TGF-b activity. Transgenic mice car-
rying this construct were crossed with Emilin1 mutant
mice, and expression of the GFP reporter gene in aorta
was revealed with anti-GFP antibodies on histological
sections. The intensity of immunochemical reaction was
higher in the mutant than in the wild-type background (Fig-
ures 4D and 4E), indicating an increased activation of the
CAGA12 promoter in Emilin1-deficient aorta.
Together, our biochemical and functional evidence re-
vealed an intriguing role for Emilin1 in the control of TGF-
b activity that may be functionally relevant in the context
of blood vessels. If Emilin1 acts within the TGF-b pathway
to promote vascular remodeling and hypertension, the re-
duction of TGF-b1 gene dosage should attenuate the mu-
tant phenotype. Strikingly, inactivation of one TGF-b1 al-
lele in Emilin1 null animals was sufficient to bring blood
pressure levels back to normal (Figures 4G and 4I, com-
pare Emilin1/;TGFb1+/+ with Emilin1/;TGFb1+/ mice).Figure 2. Emilin1 Inhibits Nodal/TGF-b Signaling through the EMI Domain
(A) Schematic representation of the structure of Emilin1 protein. The EMI domain at the N terminus is a cysteine-rich region distinctive of the EDEN
protein family.
(B–E) Overexpression of Emilin1 attenuates mesoderm development in Xenopus embryos through the EMI-domain. Eight cell-stage embryos were
injected in the marginal zone with mRNAs encoding for full-length Emilin1 (2 ng) (C), EMI-domain alone (400 pg) (D), or a deleted version of Emilin1 (2
ng, Emilin1DEMI) lacking the EMI-domain (E). The embryos were processed by in situ hybridization for the paraxial mesoderm marker MyoD. Similar
results were obtained by staining gastrula stage embryos with the pan-mesodermal marker VegT (Figure S2).
(F and G) Emilin1 inhibits nodal/TGF-b signaling, and this requires the EMI-domain. Two cell-stage embryos were injected in the animal pole with the
indicated mRNAs. Animal caps were explanted at stage 9 and harvested at stage 11 for RT-PCR analysis. (F) Activation of the mesoderm markers
Eomes and Mixer by Xnr-1 mRNA (60 pg) is antagonized by Emilin1 mRNA but not by Emilin1DEMI mRNA. (G) Overexpression of EMI-domain mRNA
is sufficient to inhibit mesoderm induction by coinjected Xnr-1. As shown in Figure S2, induction of ectopic bottle cells or axial structures, typical
effects of TGF-b/Nodal/Smad signaling, is also antagonized by Emilin1.
(H) RT-PCR of animal caps explanted from embryos injected as in (F) with constitutive-active (ca)-TGF-b type I receptor (Alk5)mRNA (100 pg) alone or
in combination with EMI-domain mRNA (800 pg). Emilin1 acts upstream of TGF-b receptor activity.
(I–K) Embryos were injected as in (F) with EMI-domain mRNA (800 pg) in combination with BMP2, eFGF, or Xwnt8 mRNAs (100 pg, 2 pg, and 20 pg,
respectively). Explanted animal caps were analyzed by RT-PCR for the indicated markers. EF1a serves as loading control.Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 935
Figure 3. Emilin1 Inhibits Cleavage of the Mature TGF-b1 Ligand from the proTGF-b1 Precursor
(A) EMI-domain does not compete with radiolabeled recombinant TGF-b1 for binding to type II TGF-b receptor. Anti-HA immunoprecipitates were
resolved by SDS-PAGE prior to autoradiography. Cold TGF-b1, though not EMI-domain, inhibits complex formation.
(B) Emilin1 inhibition of TGF-b1 signaling depends on its EMI-domain. The CAGA12-lux reporter (100 ng/2 cm well) was transfected in HEK293T cells
alone or in combination with Emilin1 expression plasmids (500 ng) as indicated. After transfection, cells were either left untreated (white bars) or
treated overnight with 5 ng/ml recombinant TGF-b1 (black bars—lanes 1 and 2). In lanes 3–6, cells were cotransfected with Emilin and proTGF-b1936 Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc.
Moreover, upon reduction of TGF-b1 gene dosage, the
size of Emilin1/ vessels returned normal in both resis-
tance (Figure 4H) and conductance (Figure 4I) districts.
The reduced size ofEmilin1/ blood vessels suggested
a role for Emilin1 as a positive regulator of cell proliferation.
Indeed, TGF-b is well known to deliver a potent cytostatic
signal to diverse cell types, including primary smooth mus-
cle cells (SMC) (Siegel and Massague, 2003; Khanna,
2004). To explore this possibility, we isolated primary
SMC from aortas of wild-type and Emilin1 mutant 15-
day-old mice and measured their growth capacity using
an in vitro cell proliferation assay. Mutant SMC showed
a significant reduction of proliferation compared with
wild-type cells (Figure S4A). These results are consistent
with the notion that an enduring activation of the TGF-b
cascade from early stages of development to adult life
generates a negative bias on growth in vascular cells, as
observed in the generalized reduction of blood vessels
size in Emilin1-deficient mice. Accordingly, we found a re-
duced level of c-Myc expression in aortic tissue explanted
from Emilin1 mutant mice (Figure S4B). c-Myc is a nega-
tively regulated direct target of TGF-b/Smad signaling,
and its repression is pivotal for ligand-mediated activation
of p21WAF1 and p15INK4b CDK inhibitors (Siegel and Mas-
sague, 2003). Remarkably, c-Myc levels returned to nor-
mal in aortas taken from the combined Emilin1 null/
TGF-b+/ mutants (Figure S4B, lane 3), a finding in line
with the rescue of the vascular phenotype (Figure 4G–4I).Taken together, these data support the notion that Emilin1
is a novel inhibitor of TGF-b availability in vivo.
Emilin1 is not the only ECM protein suggested to regu-
late TGF-b signaling. The case of Fibrillin-1 deserved par-
ticular attention, as it has been shown to be a negative reg-
ulator of TGF-b. In transgenic mouse models of Marfan
syndrome, the increased volume of lung alveoli has been
correlated with upregulation of TGF-b reporter CAGA12,
the same used here. This lung phenotype can be cured
with inactivating antibodies for TGF-b (Neptune et al.,
2003). These data raised the possibility that Emilin1 may
be influencing TGF-b signaling by a secondary mecha-
nism through Fibrillin-1. We therefore investigated the
consequences of Emilin1 deficiency on deposition and
maintenance of Fibrillin-1 microfibrils. The pattern of distri-
bution of Fibrillin-1 was indistinguishable in Emilin1+/+ and
Emilin1/ aortas and MEFs (Figures S5A–S5D). These re-
sults rule out the presence of major abnormalities of the
microfibrillar system in Emilin1 mutants.
Like Fibrillin-1, Emilin1 is expressed at high levels in lung
(Braghetta et al., 2004). The Fibrillin-1 paradigm maintains
that excess TGF-b should lead to increased alveolar
spaces (Neptune et al., 2003). This hypothesis was vali-
dated experimentally by histological analysis. As shown
in Figures 4J–4L and quantitatively analyzed in
Figure 4N, lack of Emilin1 induced a significant increase
of alveolar dimensions, as did Fibrillin-1 deficiency. The
identification of such TGF-b-dependent phenotype clearlyexpression plasmids, encoding for the C223S/C225S mutant that does not require acidic activation (40 ng). Values indicate mean ± sd. Note that
Emilin cannot antagonize mature TGF-b1. Accordingly, we found in heterologous frog assays that recombinant, fully processed hActivin was not
antagonized by Emilin1 mRNA expressing cells (data not shown).
(C and D) Primary MEFs were transfected with the TGF-b reporter p15-lux. The higher transcriptional response in Emilin1/ cells is reversed to wild-
type levels upon treatment with the TGF-b receptor inhibitor SB431542 (C) and fostered by the JNK inhibitor SP600125 (D). Values are mean ± sd.
(E) Emilin1 interacts with proTGF-b1. HEK293T cells were transfected with the proTGF-b1 and Flag-tagged EMI domain-GPI expression plasmids
(8 mg/10 cm diameter dish). Cell lysates were subjected to immunoprecipitation (anti-Flag) and Western blot (anti-LAP). In similar experimental setups,
we found that the overexpressed EMI domain can also interact with proActivin-HA, proNodal-HA, and proTGF-b3-HA (data not shown).
(F) The small latent complex does not interact with Emilin1. Immunoprecipitation (anti-Flag antibody) of HEK293T cells transfected with the expression
plasmid for Flag-tagged EMI-domain-GPI and supplemented with recombinant LAP or precomplexed LAP/TGF-b or cotransfected with proTGF-b1
expression plasmid. Anti-LAP immunoblotting reveals a specific interaction with proTGF-b.
(G) Overexpressed TGF-b interacts with endogenous Emilin1. HEK293T cells were transfected with proTGF-b alone and processed as in (E) to reveal
the copurification of endogenous Emilin1.
(H) Emilin1 inhibits proTGF-b1 processing. HEK293T cells were transfected with the indicated expression plasmids for proTGF-b1 (1 mg/3.5 mm
diameter plate), Emilin1 (2 mg), and EMI domain (1 mg). Western blotting of the cell lysates (cell layer) and of the conditioned supernatants (medium)
shows that transfected proTGF-b1 is cleaved into LAP and mature TGF-b1 by endogenous convertases’ activity (lane 1), which are inhibited in the
presence of EMI domain (lane 2) or full-length Emilin1 (lane 3).
(I) Emilin1 phenocopies furin inhibition. HEK293T cells were transfected as in (F). Where indicated, cells were treated with the furin inhibitor
RVKR-CMK. The conditioned medium was analyzed by immunoblotting with anti-Flag antibody.
(J) EMI domain inhibits cleavage of proTGF-b1 by overexpressed furin/SPC1. HEK293T cells were transfected with the indicated expression plasmids
for proTGF-b1 (1 mg/3.5 mm diameter plate), furin/SPC1 (2 mg), and EMI domain (2 mg). Overexpression of SPC1 enhances cleavage of proTGF-b1
(black arrowhead, lane 2), and this effect is reversed by overexpression of EMI domain (lane 3). This effect is specific, as EMI domain does not interfere
with proBMP processing (Figure S3B).
(K) Emilin1 is required to prevent proTGF-b cleavage. Lanes 1 and 2, wild-type and Emilin1 mutant MEFs expressing transfected proTGF-b; lane 3,
inhibition of furins rescues proTGF-b stability in mutant cells but has no effect on wild-type cells (data not shown).
(L and M) Emilin1 inhibits proTGF-b activity in the extracellular space. Cell mixing experiments were carried out as described in the text. Abbreviations
are: R, responding cells; Mock, control-untreated cells; S, stimulator cells producing proTGF-b; +E indicates that cells were also transfected with
Emilin1 expression plasmid. Note that in lane 5 of (L) Emilin1 is efficient in blocking signaling when expressed in cells not producing proTGF-b. In
(M), abbreviations are: wt, wild-type MEFs; wtR, Responding wild-type MEFs; ko, Emilin1 knockout MEFs; koR, Responding Emilin1 knockout
MEFs; koS, Stimulator Emilin1 knockout MEFs; wtS, Stimulator wild-type MEFs. Values indicate mean ± sd.
(N) Emilin1 must be secreted to antagonize TGF-b signaling. Overexpression of Emilin-tagged with KDEL is incapable of antagonizing the effect of
cotransfected proTGF-b. Inset: Western blot showing comparable expression levels of the transfected proteins. The increased signaling in Emilin-
KDEL-expressing cells suggests a dominant negative effect on endogenous Emilins. Values indicate mean ± sd.Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 937
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supports our model on the genetic and functional link be-
tween Emilin1 and TGF-b. Moreover, the similarity of the
lung phenotype constituted an ideal setting for testing
the epistatic relationship between Emilin1 and Fibrillin-1.
If Emilin1 acted through Fibrillin, one should expect that
loss of Emilin1 had no major effects on the Fibrillin mutant
phenotype. On the contrary, the results showed that si-
multaneous mutation of the two genes greatly aggravated
the alveolar phenotype (Figures 4M and 4N), favoring the
idea that Emilin1 and Fibrillin act primarily through inde-
pendent/parallel pathways to regulate TGF-b signaling.
This is also supported by the histological analysis of the
fine morphology and dimensions of elastic lamellae of aor-
tas explanted from double knockout mice as well as of
mice survival kinetics (Figures S5E– S5K).
DISCUSSION
Emilin1 Is a proTGF-b Antagonist
This paper has identified a new mechanism of regulation of
arterial blood pressure based on the function of the elastic
fiber glycoprotein Emilin1 as modulator of TGF-b signaling
(Figure 5).
Using Xenopus embryos and human cells as read-outs
of TGF-b activity, we established a role for Emilin1 as
antagonist of TGF-b signals. We found that Emilin1 over-
expression is unable to contrast the activity of mature
TGF-b1 but is effective against the immature proTGF-b.
Moreover, by using cells derived from the Emilin1 knock-
out mice, we showed that, at the physiological level,
Emilin1 is required to dampen TGF-b activity. This biolog-
ical property parallels with the specific physical interaction
of Emilin1 with proTGF-b. This represents a novelty in the
mechanisms of action of secreted antagonists of growth
factors, such as Chordin or Cerberus/Dan, as these mole-
cules antagonize mature, fully processed ligands and
compete with their cognate receptors (Piccolo et al., 1999).
Mechanism of Emilin1 Activity
We have presented evidences indicating that Emilin1 pre-
vents the processing of proTGF-b into LAP and matureTGF-b, a key event for TGF-b availability. Overexpression
of Emilin1 promotes the accumulation of unprocessed
proTGF-b at the expense of mature TGF-b; oppositely,
proTGF-b1 is readily cleaved in Emilin1 mutant cells, and
its stability can be rescued upon blockade of furin prote-
ases (Figure 3H).
Finding a new tier of regulation at the level of TGF-bmat-
uration was interesting, as previous studies focused pri-
marily on downstream events, including proper localiza-
tion of the latent LAP/TGF-b complex within the
extracellular milieu (Koli et al., 2004), and on factors ex-
posing mature TGF-b to its receptors (Figure 5). In con-
trast, the study of the very initial steps controlling TGF-b
bioavailability, such as secretion and processing, received
much less attention, likely due to the lack of specific genes
or animal models for molecules controlling these pro-
cesses. The identification of Emilin1 and the generation
of Emilin1 mutant animals represent a step forward in
this field.
Our data suggest that Emilin1 prevents proTGF-b pro-
cessing in the extracellular space, as expected for an
ECM molecule. First, artificial retention of Emilin1 within
the secretory pathway does not inhibit TGF-b activity
(Figure 3N), suggesting that Emilin1 must operate in the
extracellular compartment to act as antagonist. Second,
by mixing distinct cell populations, we found that Emilin1
is required and sufficient to counteract TGF-b even when
present only in cells receiving the signal (Figures 3L and
3M). These data are in line with reports from Constam
and coworkers, who showed that SPC/furin proteases
are required extracellularly to process TGF-b and must
act non-cell-autonomously during embryonic develop-
ment (Beck et al., 2002).
In Vivo Requirements of Emilin1 as TGF-b
Antagonist for Blood Pressure Control
In addition to in vitro studies, we validated in vivo the rele-
vance of Emilin1 as TGF-b antagonist by examining cells
and tissues from Emilin1 knockout mice. A great deal of
evidence supports our conclusion, at least in the vascularFigure 4. Increased TGF-b Activity Is Required for the Development of the Emilin1 Phenotype
(A and B) Increased TGF-b signaling in Emilin1-deficient aorta as revealed by anti-P-Smad2 immunoperoxidase staining of ascending aorta. Age of
mice: 2 months. Bar = 25 mm.
(C) Quantitative evaluation of the increase of the number of P-Smad2 positive nuclei in mutant mice. Values are mean ±SD. *p < 0.01 versus wild-type.
(D and E) Increased TGF-b signaling in Emilin1-deficient aorta as revealed by expression of theCAGA12/GFP transgene. The CAGA2/GFP transgene
was developed into Emilin1+/+ and Emilin1/ backgrounds, and corresponding sections from ascending aortas were stained in parallel with an an-
tibody against GFP using the immunoperoxidase procedure. Age of mice: 2 months. Bar = 25 mm.
(F) Activation of the TGF-b target gene PAI-1 in Emilin1-deficient aorta revealed by Western blotting. +/+ wild-type animal;/ Emilin1mutant animal.
Age of mice: 8 months.
(G and H) Dependence of the Emilin1 phenotype from TGF-b1 gene dosage. Mice with the indicated genotypes were generated by crossingEmilin1+/
and TGF-b1+/ double heterozygous animals. (G) Systolic blood pressure evaluated noninvasively by tail-cuff plethysmography in conscious mice
(n = 6 for each genotype). *p < 0.01 versus Emilin1+/+;TGFb1+/+ mice. (H) Media cross-sectional area (MCSA) of mesenteric arteries evaluated using
a Mulvany myograph (n = 5 for each genotype). *p < 0.01 versus Emilin1+/+;TGFb1+/+. Data are mean ± sem.
(I) Representative echocardiographic analysis of ascending aorta in offspring from Emilin1+/ and TGF-b1+/ crossings (n = 4 for each genotype).
(J–M) Histological sections of lung from mice generated from Emilin1 and Fibrillin-1 double heterozygous crosses. Emilin1 (K) and Fibrillin-1 (L) mutant
mice (/ and mgR, respectively) show enlarged alveolar spaces. mgR mutation is a severe hypomorphic Fibrillin-1 allele, which was always used
here in homozygosity (mgR/mgR). The alteration is further increased in double homozygous mutants (M). Bar = 50 mm.
(N) Quantitative evaluation of the effect described in (J–M). *p < 0.001 versus wild-type.Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 939
Figure 5. Model of Emilin1 Activity as Antagonist of TGF-b Signaling in the Vascular Wall
(A) The TGF-b precursor (proTGF-b) is cleaved by proprotein convertases, giving rise to the formation of the LAP-TGF-b complex; Emilin1 inhibits
this processing step. On its turn, the LAP-TGF-b complex (or small latent complex) becomes localized and specifically targeted to the extracellular
milieu by LTBP proteins (B). LTBPs are also required for TGF-b activation, namely, the retrieval of free mature TGF-b from the LAP (Koli et al., 2004).
TGF-b activation is also stimulated by avb6 integrin and other ECM molecules, such as Thrombospondin-1 (Annes et al., 2003). Signaling through the
TGF-b receptor (TGFBR) results in changes of gene expression (C), with consequences on vascular SMC growth and phenotype, ECM homeostasis,
and vascular remodeling (D).system. First, the level of P-Smad2 staining increased in
Emilin1 mutant aortas when compared to the wild-type tis-
sue (Figure 4C), as expected from the loss of a TGF-b in-
hibitor. Second, transcription from a transgenic TGF-b re-
porter was enhanced in the Emilin1 mutant background.
Third, the endogenous levels of TGF-b target genes,
such as PAI-1 and c-Myc, are dysregulated in vascular
explants from Emilin1 mutants. Further, we found an
abnormal increase of alveolar airspace in Emilin1 mutants,
a developmental defect previously linked to excess of
TGF-b signaling (Neptune et al., 2003).
Our data support the notion that the antagonism to TGF-b
is crucial to explain hypertension in Emilin1 deficient an-
imals. Indeed, we found that lowering back TGF-b levels is
sufficient to rescue the vascular defects and the blood
pressure to normal levels. Whether defects in Emilin1 un-
derlie some forms of human hypertension remains to be in-
vestigated; yet our study unveils the importance of consid-
ering mechanisms affecting TGF-b signaling to shed light
on this human disease. Of note, variations in the TGF-b sig-
nal peptide that may enhance the production of the cyto-
kine have been already correlated to increased risk of hy-
pertension in humans (Suthanthiran et al., 2000). In Emilin1
mutants, hypertension is likely caused by developmental
perturbation on vessel size; nevertheless, this perturbation
might predispose to a late-onset, seemingly acquired dis-
ease, bringing about an increased peripheral resistance.
Intriguingly, studies in the spontaneous hypertensive rat
model revealed that the hypertension has its incipit in the
reduced lumen of the resistance vasculature; still, the hy-
pertensive phenotype is not manifest in young animals
(Mulvany, 2002). These remain largely unexplored fields.940 Cell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc.We think that a relevant cause of the Emilin1 phenotype
is the reduced vascular growth due to excess of TGF-b sig-
naling. Accordingly, we found reduced proliferation ca-
pacity of primary SMC isolated from mutant vessels.
This result parallels with the level of c-Myc, a TGF-b re-
pressed target and key mediator of SMC proliferation
(Khanna, 2004): c-Myc levels are reduced in mutant aortas
but rescued in the compound Emilin/;TGF-b+/ genetic
setup. That said, TGF-b is a potent cytokine with multiple
target genes; therefore, its dysregulation might trigger
pleiotropic effects, including changes in growth factor re-
sponsiveness, cellular fate, differentiation, tissue renewal,
and others. For instance, we did document in Emilin1 mu-
tant aortas a mild fibrosis (increased collagen I deposition)
a well-known effect of persistent TGF-b activity (Fig-
ure S6).
The Emilin1 Mutant Phenotype
Elastic fibers are made of two distinct morphological com-
ponents, an amorphous core, composed mainly by the fi-
brous protein Elastin, and a coat of microfibrils, whose ma-
jor constituent is Fibrillin-1, the gene affected in patients
with Marfan syndrome (Dietz et al., 1991). Since Fibrillin-
1 has been shown to be a negative regulator of TGF-b ac-
tivity in some tissues (Neptune et al., 2003), an aspect that
deserves discussion is the comparison between the
Emilin1 and the Fibrillin-1 phenotype. In principle, the pos-
sibility existed that the Emilin1 defects might be secondary
to compromised Fibrillin-1 function. However, our data do
not favor this possibility: Not only was the Fibrillin-1 net-
work normal in Emilin1-deficient tissues, but we found
no evidence of an epistatic relationship between Emilin1
and Fibrillin-1. Indeed, the simultaneous mutation of the
two genes concurred in aggravating their similar lung phe-
notype, and the aortic defects in double knockout mice
were a combination of those found in single mutants (Fig-
ure 4). Thus, Emilin1 and Fibrillin-1 may regulate TGF-b
either through qualitatively different mechanisms or by
acting at different developmental stages. One possibility
is that Emilin1 might be primarily required during early ves-
sel morphogenesis, and its absence might impose a bias
on vascular cell growth, leading to hypoplasia and hyper-
tension; the prominent role of Fibrillin-1 in elastic matrix
and vascular wall homeostasis would emerge and domi-
nate at later stages.
Considering the extent of regulation caused by Emilin1
in cultured MEFs and aortas, the phenotype of Emilin1
might appear surprisingly mild. Yet several mechanisms
might intervene to attenuate and balance the effects of
Emilin1 in the whole organism. First, the Emilin family en-
lists seven proteins, allowing for a high complexity of reg-
ulation of TGF-b signaling by EMI-domains: Redundancy
between family members might compensate for Emilin1
inactivation. Second, one has to consider that the expres-
sion pattern of Emilin1 and of its relative TGF-b ligands
should closely overlap in order for the two molecules to
control a phenotypic trait. For instance, although Nodal
is blocked by Emilin1 in heterologous assays, Emilin1
and its family members are not coexpressed with Nodal
in early embryos: Thus, Emilin1 knockouts develop nor-
mally, without mesodermal expansion. Conversely, TGF-b1
is essential for development and homeostasis of the vas-
cular system (Agrotis et al., 2005); in line, the sole TGF-b1
haploinsufficiency is sufficient to rescue the vascular phe-
notype of Emilin1 mutants. Third, while processing of
proTGF-b1 appears as an essential step for TGF-b avail-
ability in the cells and tissues here investigated, in other
contexts downstream extracellular events may become
rate-limiting, including the mobilization of the latent TGF-b
from the extracellular matrix or its activation prior to recep-
tor binding (Figure 5). Finally, a further level of complexity
is the presence of feedback loops between TGF-b family
members, BMPs, and their extracellular regulators: This
would lead to a fine-tuning of signaling and to the appear-
ance of context- or tissue-restricted phenotypes (Koli
et al., 2004).
The discovery of Emilin1 as regulator of TGF-b process-
ing and activation may be relevant not only for hyperten-
sion but also for many other pathological conditions in
which TGF-b has been suggested to play a role, such as




Generation of mice with one inactivated Emilin1 allele was as previ-
ously described (Zanetti et al., 2004).
Mice carrying a null mutation in the TGF-b1 gene on a mixed
SvEv129  C57BL/6 background were kindly provided by Dr. A.B.
Roberts (National Cancer Institute, National Institutes of Health, Be-thesda, MD, USA). These mice were mated with Emilin1/ mice de-
rived from C57BL/6NCrlBR backcrosses. Emilin1/ and Emilin1+/+
mice harboring a reporter gene sensitive to TGF-b signaling were gen-
erated by appropriate breeding of the Emilin1/ animals with the
CAGA12/GFP transgenic strain (obtained from Dr. H.C. Dietz).
Mice with themgR hypomorphic mutation of theFibrillin-1gene were
provided by Dr. F. Ramirez.
Evaluation of Blood Pressure, Echocardiographic Analysis,
and Vessel Extensibility
Blood pressure was evaluated noninvasively by tail-cuff plethysmogra-
phy. For radiotelemetric analysis, the left femoral artery of anaesthe-
tized mice was exposed and cannulated with a 0.4 mm catheter con-
nected to a radiotelemetric device (TA11PA-C20, Data Sciences
International) anchored subcutaneously. After recovery (7 days), blood
pressure and heart rate were monitored continuously six times a day
for 20 days. Mean value was calculated with the software DQ ART
1.1 Gold (Data Sciences International).
Echocardiographic analysis was performed as previously described
(De Acetis et al., 2005) using either a 7.5 MHz or a 30 MHz imaging
transducer. For vessel extensibility evaluation, carotid artery was
placed in a pressure myograph on an inverted microscope connected
to a charge-coupled device camera and a computer system, allowing
continuous measurement of internal and external diameter. Intravas-
cular pressure was increased stepwise from 20 to 200 mmHg. Exten-
sibility was calculated using the following formula: extensibility at
a defined pressure (p) = ([diameter at p + 25 mmHg  diameter at
p  25 mmHg] / [diameter at p  25 mmHg])  100.
Plasmids
For the complete list of plasmids, please refer to Supplemental Data.
Biological Assays in Xenopus
Xenopus embryos manipulations, capped mRNA preparations, and
whole-mount in situ hybridizations were performed as previously de-
scribed (Piccolo et al., 1999). For RT-PCR, conditions and primers
were as described in http://www.hhmi.ucla.edu/derobertis/.
Cell Culture and Transfection
For luciferase assays, HEK293T cells were transfected with the indi-
cated plasmids using Lipofectamine2000 (Invitrogen); embryonic fi-
broblasts (MEFs) from wild-type and knockout Emilin1 mice were
transfected using LipofectAMINE PLUS (Invitrogen). pCMV-lacZ was
used to normalize for transfection efficiency.
For experiments in Figures 3I and 3K, cells were incubated with
100 mM decanoyl-RVKR-chloromethylketone (Alexis), adding the com-
pound every 12 hr, whereas controls were treated with carrier alone.
For experiments shown in Figure 3C, MEFs cells were incubated with
5 mM SB431542 (Tocris) for 48 hr in DMEM supplemented with 2%
FBS. For experiments in Figures 3D and 3M, MEFs cells were incu-
bated with 20 mM SP600125 (Calbiochem) for 48 hr in DMEM supple-
mented with 2% FBS. For cell-mixing experiments, Responding and
Stimulator cell populations were trypsinized and mixed together and
replated (for Stimulator MEFs in Figure 3M, after mixing, cells were cul-
tured in media without drug). After 36 hr starvation in DMEM supple-
mented with 0.1% FBS (HEK293T cells) or after 18 hr starvation in
DMEM supplemented with 2% FBS (MEFs), cells were harvested for lu-
ciferase assay. Every sample was transfected in triplicate, and every
experiment was repeated at least two times.
Immunoprecipitation and Protein Blotting
HEK293T cells were transfected with the calcium-phosphate method.
Cells were harvested in ice-cold 25 mM Tris pH 7.5, 150 mM NaCl, 2.5
mM EDTA, 10% Glycerol, 1% NP40, protease inhibitors (Roche); NP40
was diluted to 0.1% for IP. Where indicated, 150 ng purified recombi-
nant LAP (R&D) was added to lysates prior to IP (Piccolo et al., 1999).
For Western blotting, protein samples were resolved under reducing orCell 124, 929–942, March 10, 2006 ª2006 Elsevier Inc. 941
nonreducing (Figure 3E only) conditions by SDS-PAGE and blotted
onto PVDF membranes. Please refer to Supplemental Data for details
on the immunodetection procedure.
Supplemental Data
Supplemental Data include six figures, one table, Experimental Proce-
dures, and References and can be found with this article online at
http://www.cell.com/cgi/content/full/124/5/929/DC1/.
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